Morgan Stanley Soligenix, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.4 - $168.0 $801 - $336,504	2,003 Added 26.93%	9,442 $4,000
Q3 2022 Nov 14, 2022	SELL	$0.51 - $117.79 $510 - $117,907	-1,001 Reduced 11.86%	7,439 $3,000
Q2 2022 Oct 27, 2022	SELL	$0.4 - $0.75 $39 - $74	-99 Reduced 1.16%	8,440 $5,000
Q2 2022 Aug 15, 2022	SELL	$0.4 - $0.75 $39 - $74	-99 Reduced 1.16%	8,440 $5,000
Q1 2022 Oct 27, 2022	BUY	$0.61 - $0.75 $60 - $74	99 Added 1.17%	8,539 $6,000
Q1 2022 May 13, 2022	BUY	$0.61 - $0.75 $333 - $409	546 Added 6.83%	8,539 $6,000
Q4 2021 Feb 14, 2022	SELL	$0.66 - $1.1 $790 - $1,316	-1,197 Reduced 13.03%	7,993 $5,000
Q3 2021 Nov 15, 2021	BUY	$0.9 - $1.31 $8,271 - $12,038	9,190 New	9,190 $10,000

Ticker SNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,105,200
Market Cap $125M
Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has c...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.